Increased expression of EphA2 is correlated with cancer progression, metastatic spread, and patient survival [1, 2], and overexpression of EphA2 has been shown to specifically increase migration, invasion, metastasis, and angiogenesis [19–24]. Here, EPHA2 is linked to cancer.